Intercept Pharmaceuticals Inc organizacji Current ratio
Jaka jest wartość Current ratio organizacji Intercept Pharmaceuticals Inc?
Wartość Current ratio organizacji Intercept Pharmaceuticals Inc to 4.22
Jaka jest definicja Current ratio?
Wskaźnik bieżącej płynności to wskaźnik płynności, który określa, czy firma ma wystarczające zasoby, aby wywiązać się z zobowiązań krótkoterminowych.
The current ratio is an indication of a company's liquidity and measures the capability to meet a company's short-term obligations. It compares a firm's current assets to its current liabilities, and is expressed as current assets divided by current liabilities. The ratio is only useful when two companies are compared within industry because inter industry business operations differ substantially. To determine liquidity, the current ratio is not as helpful as the quick ratio, because it includes all those assets that may not be easily liquidated, like prepaid expenses and inventory.
Acceptable current ratios vary from industry to industry. In many cases an investor would consider a high current ratio to be better than a low current ratio, because a high current ratio indicates that the company is more likely to pay the investor back. Large current ratios are not always a good sign for investors. If the company's current ratio is too high it may indicate that the company is not efficiently using its current assets or its short-term financing facilities. If current liabilities exceed current assets the current ratio will be less than 1. A current ratio of less than 1 indicates that the company may have problems meeting its short-term obligations.
Some types of businesses can operate with a current ratio of less than one however. If inventory turns into cash much more rapidly than the accounts payable become due, then the firm's current ratio can comfortably remain less than one. Inventory is valued at the cost of acquiring it and the firm intends to sell the inventory for more than this cost. The sale will therefore generate substantially more cash than the value of inventory on the balance sheet. Low current ratios can also be justified for businesses that can collect cash from customers long before they need to pay their suppliers.
Current ratio firm w Health Care sektor na NASDAQ w porównaniu do Intercept Pharmaceuticals Inc
Czym się zajmuję organizacja Intercept Pharmaceuticals Inc?
we are a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive, non-viral liver diseases, including primary biliary cholangitis (pbc), nonalcoholic steatohepatitis (nash), primary sclerosing cholangitis (psc) and biliary atresia. in a new age of liver disease treatment, our team is developing vital therapies to meet the needs of those living with progressive, non-viral liver disease. we are committed to improving patients’ lives and addressing the liver community’s most pressing needs. our corporate headquarters is located in new york, and we have additional offices in san diego, london and perugia. for more information about intercept, please visit our website at: www.interceptpharma.com and follow us on twitter at: @interceptpharma.
Firmy z current ratio podobne do Intercept Pharmaceuticals Inc
- Wartość Current ratio organizacji Ardelyx Inc to 4.21
- Wartość Current ratio organizacji Minerva Intelligence to 4.21
- Wartość Current ratio organizacji Meteorite Capital to 4.21
- Wartość Current ratio organizacji Beng Soon Mach Hldg Ltd to 4.22
- Wartość Current ratio organizacji Vision Cinemas to 4.22
- Wartość Current ratio organizacji GrafTech International to 4.22
- Wartość Current ratio organizacji Intercept Pharmaceuticals Inc to 4.22
- Wartość Current ratio organizacji Control Print to 4.22
- Wartość Current ratio organizacji Magnum Mining and Exploration to 4.22
- Wartość Current ratio organizacji Aligos Therapeutics to 4.23
- Wartość Current ratio organizacji Vongroup to 4.23
- Wartość Current ratio organizacji Laurent-Perrier SA to 4.23
- Wartość Current ratio organizacji ALE Property Stapled Securities to 4.23